Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Stopped early · Phase 2

Conditions studied: Vitreomacular Traction, Subretinal Edema

In brief

Evaluate the efficacy of eplerenone as an adjunctive treatment to intravitreal ocriplasmin for subretinal fluid in comparison to a control group of only receiving intravitreal ocriplasmin in patients with symptomatic vitreomacular adhesion.

Key facts

Study ID

NCT04300881

Run by

Wagner Macula & Retina Center

People needed

2

Starts

2019-10-04

Expected to finish

2021-01-05

Last updated by the study team

2021-01-08

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age > 18 years of age
• Symptomatic VMA, VMT, or macular hole
• BCVA 20/30 - CF 3' Snellen equivalent
• Willing and able to provide signed informed consent and willing to undertake all scheduled study-related assessments, visits, and treatments
• JETREA® treatment naïve

You may not qualify if…

• Patients who are pregnant, planning to become pregnant, or breastfeeding a child
• Uncontrolled ocular hypertension or glaucoma in study (defined as IOP ≥ 25mm Hg or a cup to disc ratio (CDR) > 0.8 despite treatment with anti-glaucoma medication)
• Active malignancies within the last 12 months except appropriately treated carcinoma in situ of the crevices, melanoma, and prostate cancers treated with a curative intent
• Inability to comply with study or follow-up procedures
• Women who may become pregnant or lactating or intend to become pregnant during the study
• Known drug allergy to ocriplasmin or eplerenone
• Patients with known contraindications Eplerenone as outlined in the package insert

Where it is running

• Wagner Macula & Retina Center — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.